AR082686A1 - Adyuvantes de vacuna que direccionan a los adyuvantes de anticuerpos directamente hacia las celulas presentadoras de antigenos - Google Patents
Adyuvantes de vacuna que direccionan a los adyuvantes de anticuerpos directamente hacia las celulas presentadoras de antigenosInfo
- Publication number
- AR082686A1 AR082686A1 ARP110102955A ARP110102955A AR082686A1 AR 082686 A1 AR082686 A1 AR 082686A1 AR P110102955 A ARP110102955 A AR P110102955A AR P110102955 A ARP110102955 A AR P110102955A AR 082686 A1 AR082686 A1 AR 082686A1
- Authority
- AR
- Argentina
- Prior art keywords
- vaccine
- assistants
- presenting cells
- antigen presenting
- directly towards
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/106—Vibrio; Campylobacter; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37376310P | 2010-08-13 | 2010-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082686A1 true AR082686A1 (es) | 2012-12-26 |
Family
ID=45564978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102955A AR082686A1 (es) | 2010-08-13 | 2011-08-12 | Adyuvantes de vacuna que direccionan a los adyuvantes de anticuerpos directamente hacia las celulas presentadoras de antigenos |
Country Status (14)
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑 |
| CN101820910B (zh) * | 2007-05-03 | 2014-08-06 | 新加坡科技研究局 | 结合细胞内prl-1多肽或prl-3多肽的抗体 |
| WO2012122396A1 (en) * | 2011-03-08 | 2012-09-13 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| AR088220A1 (es) * | 2011-08-29 | 2014-05-21 | Baylor Res Inst | Activacion de celulas dendriticas humanas por el receptor de dectina-1 o de tipo toll 2 (tlr2) en el control de la alergia y el asma |
| WO2013134293A1 (en) * | 2012-03-05 | 2013-09-12 | Duke University | Vaccine formulation |
| CN112587671A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| WO2014031984A1 (en) * | 2012-08-24 | 2014-02-27 | Baylor Research Institute | Immunological detection methods and compositions |
| WO2014210540A1 (en) | 2013-06-28 | 2014-12-31 | Baylor Research Institute | Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis |
| CN103409451A (zh) * | 2013-06-28 | 2013-11-27 | 扬州维克斯生物科技有限公司 | 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法 |
| AU2014315081A1 (en) | 2013-09-05 | 2016-03-24 | Duke University | Nav1.7 antibodies and methods of using the same |
| EP3092256B1 (en) | 2014-01-10 | 2022-05-18 | Birdie Biopharmaceuticals Inc. | Compounds and compositions for immunotherapy |
| WO2015106281A1 (en) | 2014-01-13 | 2015-07-16 | Baylor Research Institute | Novel vaccines against hpv and hpv-related diseases |
| JP2017507922A (ja) * | 2014-01-22 | 2017-03-23 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗体のためおよび抗体が充填された樹状細胞を介した療法のための方法および組成物 |
| IL300029A (en) | 2014-05-16 | 2023-03-01 | Baylor Res Institute | Methods and preparations for the treatment of autoimmune and inflammatory conditions |
| US20170095573A1 (en) * | 2014-06-02 | 2017-04-06 | Baylor Research Institute | Methods and compositions for treating allergy and inflammatory diseases |
| MX2016017393A (es) | 2014-07-01 | 2017-09-05 | Pfizer | Diacuerpos heterodimericos biespecificos y sus usos. |
| DK4001311T3 (da) | 2014-07-09 | 2026-02-02 | Birdie Biopharmaceuticals Inc | Anti-pd-l1/pd-1-kombinationer til behandling af tumorer |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN104689313A (zh) * | 2015-03-04 | 2015-06-10 | 中国科学院海洋研究所 | 大菱鲆cd83分子作为疫苗佐剂的应用 |
| US10624964B2 (en) | 2015-05-01 | 2020-04-21 | The Trustees Of The University Of Pennsylvania | Methods and compositions for stimulating immune response using potent immunostimulatory RNA motifs |
| CR20180229A (es) | 2015-10-29 | 2018-08-24 | Novartis Ag | Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll |
| KR102810368B1 (ko) * | 2015-11-10 | 2025-05-19 | 예일 유니버시티 | 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법 |
| KR20180124014A (ko) * | 2015-12-15 | 2018-11-20 | 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) | Ebv-세포 항원 및 표적화 모이어티를 포함하는 면역원성 컨스트럭트 및 그의 응용 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN106943598A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| MX2018010485A (es) | 2016-03-04 | 2019-01-10 | Jn Biosciences Llc | Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit). |
| BR112019000071A2 (pt) | 2016-07-07 | 2019-07-02 | Bolt Biotherapeutics Inc | conjugados adjuvantes de anticorpo |
| CA3049791A1 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| CN108727503A (zh) * | 2017-04-18 | 2018-11-02 | 武汉博沃生物科技有限公司 | VZV重组gE-鞭毛素融合蛋白及其制备方法和应用 |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| FI3641771T3 (fi) | 2017-06-23 | 2026-08-11 | Birdie Biopharmaceuticals Inc | Farmaseuttisia koostumuksia |
| JP2020526482A (ja) * | 2017-06-28 | 2020-08-31 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | デクチン−2刺激及び癌免疫療法のための方法及び組成物 |
| US20210369635A1 (en) * | 2017-11-29 | 2021-12-02 | Adaptive Phage Therapeutics, Inc. | Novel methods of vaccination using icosahedral phage |
| PE20211456A1 (es) * | 2018-02-28 | 2021-08-05 | Hoffmann La Roche | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado |
| WO2020154424A1 (en) * | 2019-01-22 | 2020-07-30 | The Brigham And Women's Hospital, Inc. | Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof |
| EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| WO2020193718A1 (en) | 2019-03-27 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Recombinant proteins with cd40 activating properties |
| WO2020243616A1 (en) * | 2019-05-31 | 2020-12-03 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | E-cadherin activating antibodies and uses thereof |
| KR20220131895A (ko) * | 2019-11-21 | 2022-09-29 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 항-pd-1/il-15 면역사이토카인을 이용하여 pd-1을 표적으로 하는 신규한 면역요법 |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| US20230183366A1 (en) | 2020-05-13 | 2023-06-15 | Inserm (Institut National De La Santé Et De La Recherch Médicale) | Recombinant proteins with ox40 activating properties |
| CA3184802A1 (en) | 2020-05-26 | 2021-12-02 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes |
| TW202210514A (zh) | 2020-06-02 | 2022-03-16 | 美商阿克思生物科學有限公司 | 針對tigit的抗體 |
| KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
| CN111850006B (zh) * | 2020-07-27 | 2022-04-22 | 齐鲁工业大学 | 一种适用于低钙离子浓度的纤维小体对接蛋白组合突变体36865及应用 |
| JP2023554587A (ja) | 2020-11-12 | 2023-12-28 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | Sars-cov-2 スパイクタンパク質の受容体結合ドメインにコンジュゲートまたは融合している抗体およびワクチン目的でのそれらの使用 |
| TW202237648A (zh) * | 2020-11-18 | 2022-10-01 | 美商開拓免疫醫療公司 | 抗marco抗體及其用途 |
| US20240131138A1 (en) | 2020-12-23 | 2024-04-25 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells |
| MX2023008986A (es) | 2021-01-29 | 2023-08-15 | Inst Nat Sante Rech Med | Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna. |
| CN118555970A (zh) * | 2021-11-04 | 2024-08-27 | 总医院有限公司 | 抗间皮素抗体试剂 |
| JP2024540505A (ja) | 2021-11-17 | 2024-10-31 | アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル | ユニバーサルサルベコウイルスワクチン |
| CN119948059A (zh) | 2022-10-05 | 2025-05-06 | 法国国家健康医学研究院 | 靶向dc的抗尼帕病毒感染疫苗 |
| EP4601682A1 (en) * | 2022-10-13 | 2025-08-20 | The Brigham & Women's Hospital, Inc. | Methods and compositions for improving response to immunotherapy |
| KR102878250B1 (ko) * | 2023-01-11 | 2025-10-31 | 서울대학교산학협력단 | 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물 |
| EP4695289A1 (en) * | 2023-04-13 | 2026-02-18 | The Regents of the University of California | Isoform-independent antibodies to lipoprotein(a) |
| WO2026139467A1 (en) | 2024-12-23 | 2026-07-02 | Institut National de la Santé et de la Recherche Médicale | Methods for producing vesicles and applications thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1057915C (zh) * | 1994-09-19 | 2000-11-01 | 中国医学科学院医药生物技术研究所 | 免疫佐剂 |
| TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
| US9259459B2 (en) * | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
| WO2007103048A2 (en) * | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| ES2555544T3 (es) * | 2006-03-07 | 2016-01-04 | Vaxinnate Corporation | Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas |
| US8057798B2 (en) * | 2007-02-02 | 2011-11-15 | Baylor Research Institute | Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells |
| TWI423985B (zh) * | 2007-02-23 | 2014-01-21 | 貝勒研究協會 | 利用dectin-1活化人類抗原呈現細胞之醫療應用 |
| US8236318B2 (en) * | 2007-11-07 | 2012-08-07 | Celldex Therapeutics Inc. | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
| WO2010009346A2 (en) * | 2008-07-16 | 2010-01-21 | Baylor Research Institute | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
| BRPI1009455A2 (pt) * | 2009-03-10 | 2016-03-01 | Baylor Res Inst | anticorpos anti-c40 e usos dos mesmos |
| CN108373509A (zh) * | 2009-03-10 | 2018-08-07 | 贝勒研究院 | 靶向抗原呈递细胞的抗病毒疫苗 |
| BRPI1009454A2 (pt) * | 2009-03-10 | 2019-09-24 | Baylor Res Institute | vacinas contra o câncer direcionadas a células apresentadoras de antígenos |
| CA2798616A1 (en) * | 2010-05-07 | 2011-11-10 | Baylor Research Institute | Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells |
-
2011
- 2011-08-12 KR KR1020137006354A patent/KR20130108295A/ko not_active Withdrawn
- 2011-08-12 US US13/208,993 patent/US20120039916A1/en not_active Abandoned
- 2011-08-12 CA CA2807585A patent/CA2807585A1/en not_active Abandoned
- 2011-08-12 RU RU2013110889/10A patent/RU2013110889A/ru unknown
- 2011-08-12 JP JP2013524253A patent/JP2013535508A/ja active Pending
- 2011-08-12 AU AU2011289234A patent/AU2011289234B2/en not_active Ceased
- 2011-08-12 TW TW100128970A patent/TWI506035B/zh not_active IP Right Cessation
- 2011-08-12 BR BR112013002940A patent/BR112013002940A2/pt not_active IP Right Cessation
- 2011-08-12 MX MX2013001527A patent/MX2013001527A/es not_active Application Discontinuation
- 2011-08-12 WO PCT/US2011/047633 patent/WO2012021834A1/en not_active Ceased
- 2011-08-12 AR ARP110102955A patent/AR082686A1/es not_active Application Discontinuation
- 2011-08-12 CN CN2011800489046A patent/CN103328005A/zh active Pending
- 2011-08-12 EP EP11817128.9A patent/EP2603235A4/en not_active Withdrawn
-
2013
- 2013-02-06 ZA ZA2013/01013A patent/ZA201301013B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103328005A (zh) | 2013-09-25 |
| BR112013002940A2 (pt) | 2019-09-24 |
| TWI506035B (zh) | 2015-11-01 |
| US20120039916A1 (en) | 2012-02-16 |
| EP2603235A4 (en) | 2014-04-09 |
| TW201208696A (en) | 2012-03-01 |
| JP2013535508A (ja) | 2013-09-12 |
| KR20130108295A (ko) | 2013-10-02 |
| EP2603235A1 (en) | 2013-06-19 |
| ZA201301013B (en) | 2015-10-28 |
| AU2011289234B2 (en) | 2014-09-11 |
| WO2012021834A1 (en) | 2012-02-16 |
| AU2011289234A1 (en) | 2013-02-21 |
| RU2013110889A (ru) | 2014-09-20 |
| MX2013001527A (es) | 2013-04-24 |
| CA2807585A1 (en) | 2012-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085633A1 (es) | Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos | |
| MX2013001527A (es) | Nuevas vacunas adyuvantes en base a adyuvantes de orientacion para anticuerpos directamente hacia celulas presentadoras de antigenos. | |
| AR115939A2 (es) | Composición que contiene palmitoil-etanolamida ultra-micronizada | |
| JO3257B1 (ar) | مركبات وتركيبات كمعدلات لفاعلية tlr | |
| CO6331297A2 (es) | Composiciones adyuvantes novedosas | |
| CO6511229A2 (es) | Metodos para reducir la actividad viricida en composiciones pcv-2 y composiciones pcv-2 con una inmunogeicidad mejorada | |
| AR089578A1 (es) | Composiciones, metodos para tratar el virus de la hepatitis c y proceso de preparacion | |
| ES2721882T3 (es) | Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas | |
| CL2012000585A1 (es) | Composición inmunogénica que comprende un compuesto agonista de un receptor tipo toll 7 (tlr7) o una sal de este, un antígeno, y un adyuvante que contiene aluminio; método para mejorar la efectividad de una composición inmunogénica que comprende adicionar dicha composición que contiene un agonista de tlr7; y su uso como inmunoestimulante. | |
| CY1119269T1 (el) | Θεραπεια βλαβων που προκαλουνται απο ιους | |
| CU20140068A7 (es) | Triazolopiridinas sustituidas | |
| MX351975B (es) | Composiciones y metodos para el tratamiento de infecciones y tumores. | |
| CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| CU20120171A7 (es) | Triazolopiridinas sustituidas | |
| MX2013010343A (es) | Composicion y metodos para el transplante de microbiota de colon. | |
| NI201200139A (es) | Compuestos de sililo tricíclicos fusionados y métodos de uso de los mismos para el tratamiento de enfermedades virales. | |
| CO6690760A2 (es) | Variantes no lipidadas de antígenos orf2086 de neisseria meningitidis | |
| ECSP10010106A (es) | Trans-clomifeno para el síndrome metabólico | |
| MX2013013906A (es) | Vacunas combinadas para prevencion de infecciones por virus porcino. | |
| AR080294A1 (es) | Composiciones dirigidas a mejorar la solubilidad y administracion de los compuestos activos de magnolia | |
| AR082529A1 (es) | FORMULACIONES ESTABLES DE ANTIGENOS rLP2086 DE NEISSERIA MENINGITIDIS | |
| PE20161034A1 (es) | Composiciones y metodos para reducir eventos adversos cardiovasculares graves | |
| BR112015018270A2 (pt) | composições que compreendem 15-ohepa e métodos de uso das mesmas | |
| MX384875B (es) | Método para obtener una vacuna de mycoplasma. | |
| CL2011000877A1 (es) | Composicion inmunogena para el tratamiento y/o profilaxis de ganado contra infecciones microbiologicas porque comprende antigeno de mycoplasma bovis; metodo de coadministracion de dos o mas antigenos a un ganado bovino. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |